Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

Universitaire Ziekenhuizen KU Leuven24 enrolled

Overview

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Invasive Pulmonary Aspergillosis

Eligibility

Sex: ALLMin age: 16 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * hospitalisation in the hematology or intensive care department * age \> 16 years * informed consent * proven or probable IPA (EORTC/ MSG criteria) * galactomannan positivity in BAL or serum Exclusion Criteria: * age \< 16 years

Locations (1)

UZ Leuven

Leuven, Belgium

Outcomes

Primary Outcomes

The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC)

Time frame: 15 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.